Finally!-To The Moon - Tiger Brokers Online Investing Community - To The Moon

3
Comment
Favorite

BitcoinMaxi
2023-10-02

Finally!

Invitae Jumps 23% As FDA Clears First-of-Its-Kind Cancer Test

Genetic test developer $Invitae Corporation$ added ~23% premarket Monday after the FDA greenlighted its Invitae Common Hereditary Cancers Panel, a first-of-its-kind test to identify cancer-related genes.Using DNA extracted from a blood sample, the test analyzes 47 genes associated with an elevated risk of developing cancers in the breast, ovary, uterus, prostate, and gastrointestinal system.The in vitro diagnostic test can also help detect cancer-associated genetic variants in people who have al

Invitae Jumps 23% As FDA Clears First-of-Its-Kind Cancer Test

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

3

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":226017549455392,"tweetId":"226017549455392","gmtCreate":1696244989458,"gmtModify":1696244993852,"author":{"id":3575705860283755,"idStr":"3575705860283755","authorId":3575705860283755,"authorIdStr":"3575705860283755","name":"BitcoinMaxi","avatar":"https://community-static.tradeup.com/news/e4a0d3f31ab627d7ead179da6e16f516","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Finally!</p></body></html>","htmlText":"<html><head></head><body><p>Finally!</p></body></html>","text":"Finally!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/226017549455392","repostId":1107359409,"repostType":2,"repost":{"id":"1107359409","kind":"news","pubTimestamp":1696244589,"share":"https://www.laohu8.com/m/news/1107359409?lang=&edition=full","pubTime":"2023-10-02 19:03","market":"us","language":"en","title":"Invitae Jumps 23% As FDA Clears First-of-Its-Kind Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=1107359409","media":"Seeking Alpha","summary":"Genetic test developer $Invitae Corporation$ added ~23% premarket Monday after the FDA greenlighted its Invitae Common Hereditary Cancers Panel, a first-of-its-kind test to identify cancer-related genes.Using DNA extracted from a blood sample, the test analyzes 47 genes associated with an elevated risk of developing cancers in the breast, ovary, uterus, prostate, and gastrointestinal system.The in vitro diagnostic test can also help detect cancer-associated genetic variants in people who have al","content":"<html><head></head><body><p>Genetic test developer <a href=\"https://laohu8.com/S/NVTA\">Invitae Corporation</a> added ~23% premarket Monday after the FDA greenlighted its Invitae Common Hereditary Cancers Panel, a first-of-its-kind test to identify cancer-related genes.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/635290aceb746905dc9e1f37d5cc99ea\" tg-width=\"786\" tg-height=\"628\"/></p><p>Using DNA extracted from a blood sample, the test analyzes 47 genes associated with an elevated risk of developing cancers in the breast, ovary, uterus, prostate, and gastrointestinal system.</p><p>The in vitro diagnostic test can also help detect cancer-associated genetic variants in people who have already been diagnosed with cancer, the FDA said in a statement.</p><p>Some of the notable genes the Invitae Common Hereditary Cancers Panel detects include BRCA1 and BRCA2, which are known to be associated with breast and ovarian cancer.</p><p>The test is available on prescription, and its results are generated after lab testing a specimen collected at the point of care, such as a doctor&#39;s office.</p><p>The regulator authorized the test using its De Novo premarket review pathway based on data from 9K clinical samples, which indicated ≥99.0% accuracy for all genetic variant types tested.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invitae Jumps 23% As FDA Clears First-of-Its-Kind Cancer Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvitae Jumps 23% As FDA Clears First-of-Its-Kind Cancer Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-02 19:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4016998-invitae-stock-jumps-fda-clears-cancer-test><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genetic test developer Invitae Corporation added ~23% premarket Monday after the FDA greenlighted its Invitae Common Hereditary Cancers Panel, a first-of-its-kind test to identify cancer-related genes...</p>\n\n<a href=\"https://seekingalpha.com/news/4016998-invitae-stock-jumps-fda-clears-cancer-test\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVTA":"Invitae Corporation"},"source_url":"https://seekingalpha.com/news/4016998-invitae-stock-jumps-fda-clears-cancer-test","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1107359409","content_text":"Genetic test developer Invitae Corporation added ~23% premarket Monday after the FDA greenlighted its Invitae Common Hereditary Cancers Panel, a first-of-its-kind test to identify cancer-related genes.Using DNA extracted from a blood sample, the test analyzes 47 genes associated with an elevated risk of developing cancers in the breast, ovary, uterus, prostate, and gastrointestinal system.The in vitro diagnostic test can also help detect cancer-associated genetic variants in people who have already been diagnosed with cancer, the FDA said in a statement.Some of the notable genes the Invitae Common Hereditary Cancers Panel detects include BRCA1 and BRCA2, which are known to be associated with breast and ovarian cancer.The test is available on prescription, and its results are generated after lab testing a specimen collected at the point of care, such as a doctor's office.The regulator authorized the test using its De Novo premarket review pathway based on data from 9K clinical samples, which indicated ≥99.0% accuracy for all genetic variant types tested.","news_type":1},"isVote":1,"tweetType":1,"viewCount":407,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}